Key result
Colchicine fails to reduce mortality but cuts MI risk ~80% alongside increased GI intolerance.
Why the study?
Does colchicine reduce all-cause mortality, myocardial infarction and adverse events in adult populations?
Meta-Analysis (n=4,992)
Does colchicine reduce all-cause mortality, myocardial infarction and adverse events in adult populations?
Effect estimate: RR 0.94 (95% CI 0.82 to 1.09)
Long-term colchicine treatment does not significantly reduce all-cause mortality but may reduce myocardial infarction, though it increases gastrointestinal intolerance.
No takes yet. Share an insight, caveat, or question.
No all-cause mortality benefit with colchicine tempers routine use; extends RCT meta-analysis but leaves MI reduction open to larger confirmation.
Hemkens et al. (2016) conducted a meta-analysis in High cardiovascular risk (n=4,992). Colchicine vs. Any control was evaluated on All-cause mortality (RR 0.94, 95% CI 0.82 to 1.09). Colchicine had no effect on all-cause mortality (RR 0.94; 95% CI 0.82-1.09) but reduced the risk of myocardial infarction (RR 0.20; 95% CI 0.07-0.57) while increasing gastrointestinal intolerance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: